Compare MLYS & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | VREX |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 447.2M |
| IPO Year | 2023 | 2016 |
| Metric | MLYS | VREX |
|---|---|---|
| Price | $25.69 | $18.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $48.67 | $16.67 |
| AVG Volume (30 Days) | 656.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $811,000,000.00 |
| Revenue This Year | N/A | $5.35 |
| Revenue Next Year | N/A | $3.88 |
| P/E Ratio | ★ N/A | $80.43 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.26 | $9.09 |
| 52 Week High | $47.65 | $18.63 |
| Indicator | MLYS | VREX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 90.71 |
| Support Level | $25.53 | $9.73 |
| Resistance Level | $30.90 | N/A |
| Average True Range (ATR) | 1.14 | 0.33 |
| MACD | -0.06 | 0.77 |
| Stochastic Oscillator | 24.64 | 98.20 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.